Navigation Links
Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
Date:8/4/2009

NEW YORK, Aug. 4 /PRNewswire-FirstCall / -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that the Company and Alfa Wassermann S.p.A. have settled a dispute over issues arising from the terminated license agreement for Sulonex (sulodexide). Under the terms of the settlement agreement, Alfa Wassermann is paying Keryx US$3,500,000 (of which US$2,750,000 has already been received by Keryx and $750,000 is to be paid to Keryx on or before July 30, 2010), and Keryx shall deliver to Alfa Wassermann all of its data, information and other intellectual property related to Sulonex.

Ron Bentsur, Chief Executive Officer of Keryx, stated, "We are pleased that this matter has been resolved in a manner that we believe serves the best interests of the Keryx shareholders. This settlement provides us with additional non-dilutive cash to move our compounds into Phase 3 trials."

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex((TM)) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. Keryx is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in numerou
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
2. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
3. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
5. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
6. Keryx Biopharmaceuticals Receives Nasdaq Notification
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
8. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Respected southern ... awards in 2015, marking him as an attorney who has sharp legal skills ... both a Client Distinction Award for 2015 from Martindale-Hubbell and a Top 10 Award ...
(Date:7/6/2015)... ... July 06, 2015 , ... University of Pittsburgh Cancer ... for thyroid cancer testing to reflect newly available tests that better incorporate personalized medicine ... how to interpret thyroid cancer tests is published in the July issue of the ...
(Date:7/6/2015)... Signal Hill, CA (PRWEB) , ... July 06, 2015 , ... ... Doctors on Liens , the leading network of doctors working on a lien ... chiropractor with Doctors on Liens. , The daughter of two Cambodian refugees, Dr. Lim ...
(Date:7/6/2015)... ... 06, 2015 , ... Hundreds of thousands of people in ... why liposuction regularly ranks among the top five most popular cosmetic surgeries performed ... than a way to slim down a silhouette for swimsuit season. Military members ...
(Date:7/6/2015)... OH (PRWEB) , ... July 06, 2015 , ... ... the proper reimbursement for radiology services and ADVOCATE is leading the transition. ADVOCATE, ... their coding expertise with their Top 10 Tips for ICD-10. The ten tips ...
Breaking Medicine News(10 mins):Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2
... said today that a kitten dropped off last month at ... who may have,come into contact with the animal should call ... female about eight- to 10-weeks-old,was abandoned on or around June ... tested positive for rabies on June 27. Another kitten, a ...
... toll in outbreak reaches 869, probe expands to include ... 1 (HealthDay News) -- With the number of people ... 869, with 107 hospitalizations, U.S. officials acknowledged Tuesday that ... the contaminant. , The U.S. Food and Drug Administration ...
... Dynatronics,Corporation (Nasdaq: DYNT ) today announced that the ... the last 30 consecutive business days,the bid price of ... per,share requirement for continued inclusion under NASDAQ,s Marketplace Rules.,As ... days, or until December,22, 2008, to regain compliance. If, ...
... July 1 Grubb & Ellis Healthcare,REIT, Inc. ... a,collection of 13 healthcare-related properties comprising 20 buildings,located ... approximately 689,000 square feet of,gross leaseable area. The ... by Clarian Health Partners, which has occupancy in ...
... 5-year survival rate for those on HAART now equals ... Death rates for HIV-infected people lucky enough to get ... the introduction of these drugs in 1996, new British ... for those infected sexually is now about equal to ...
... found that a gene region known to play a ... also present in all types of childhood arthritis. The ... switch" that helps turn on the debilitating disease. , ... the link between the gene region and juvenile idiopathic ...
Cached Medicine News:Health News:U.S. Officials Stymied in Salmonella Search 2Health News:U.S. Officials Stymied in Salmonella Search 3Health News:U.S. Officials Stymied in Salmonella Search 4Health News:Dynatronics Receives NASDAQ Minimum Bid Price Deficiency Letter 2Health News:Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 3 in Indianapolis 2Health News:Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 3 in Indianapolis 3Health News:Death Rates for HIV Patients Decrease Dramatically 2Health News:Death Rates for HIV Patients Decrease Dramatically 3Health News:Pediatric researchers find possible 'master switch' gene in juvenile arthritis 2
(Date:7/6/2015)... 2015   Cepheid (Nasdaq: CPHD ) today ... 2015 second quarter ended June 30, 2015 on Thursday, ... The Company will host a management presentation ... 2015, to discuss the results.  To access the live ... at least 15 minutes before the scheduled start time ...
(Date:7/6/2015)... China Information Technology, Inc. (the "Company" or ... cloud-based platform, exchange, and big data solutions in ... launched its mobile app for Healthcare One Pass, ushering ... mobile devices. The Company jointly hosted the launch ceremony ... and Shenzhen News Net.   The mobile app ...
(Date:7/4/2015)... , Spanje, July 4, 2015 /PRNewswire/ ... Y-90 harsmicrosferen aan eerstelijns chemotherapie voor patiënten ... lever (mCRC) verlengt de progressievrije overleving in ... niet-resectabele, gemetastaseerde colorectale kanker (mCRC) die alleen ... verbetering gezien in progressievrije overleving (PFS) in ...
Breaking Medicine Technology:CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5
... EDISON, N.J., Dec. 7 Q-Med AB and Oceana Therapeutics, Inc. ... primary endpoints for the treatment of fecal incontinence. , Q-Med AB ... the FDA during the first quarter of 2010 based on the ... result of years of hard work as we developed a product ...
... , SAN DIEGO, Dec. 7 CareFusion (NYSE: ... six new Pyxis® medication management products at the 44th American ... Exhibition Dec. 6 -10 in Las Vegas. , CareFusion is ... Pyxis products rank number one in user satisfaction ratings by ...
Cached Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3
... Captique is a non-animal stabilized ... newest HA filler to enter the ... correction of moderate to severe facial ... folds). Captique is injected just under ...
... Radiesse brings you into the new ... can now offer your patients immediate, long-term ... and flexibility. This injectable filler offers superior ... cosmetic and reconstructive treatments. Long-lasting, Radiesse saves ...
The HEMOCHRON Model 401 is a portable, single-well whole blood coagulation monitoring instrument. The 401 provides on-screen plasma equivalent PT and APTT test results....
... clinically proven to reduce the appearance of ... formula combines Retinol, the purest form of ... It works deep within skin's surface to ... appearance. Fast absorbing, it has a fresh, ...
Medicine Products: